TABLE 4-4 TABLE 4-17 Maximum Recommended Dosages (MRDs) of Local Duration of Pulpal and Soft Tissue Anesthesia for Anesthetics Available in North America Available Local Anesthetics MANUFACTURER’S AND FDA (MRD) DURATION (APPROXIMATE MINUTES) Local Anesthetic mg/kg mg/lb MRD, mg m Drug Formulation Pulpal Soft Tissue Articaine With vasoconstrictor 7.0 3.2 None listed Mepivacaine 3% (infiltration) 5-10 90-120 Bupivacaine Prilocaine 4% (infiltration) 10-15 o60-120 With vasoconstrictor None listed None listed 90 Prilocaine 4% (nerve block) 40-60 120-240 With vasoconstrictor 2.0 0.9 90 Articaine 4% + epinephrine 45-60 180-240 c (Canada) 1 : 200,000 Lidocaine Lidocaine 2% + epinephrine .60 180-300 With vasoconstrictor 7.0 3.2 500 1 : 50,000 t Mepivacaine Lidocaine 2% + epinephrine 60 180-300 o No vasoconstrictor 6.6 3.0 400 1 : 100,000 With vasoconstrictor 6.6 3.0 400 Mepivacaine 2% + 60 180-300 Prilocaine levonordefrin 1 : 20,000p No vasoconstrictor 8.0 3.6 600 Articaine 4% + epinephrine 60-75 180-300 With vasoconstrictor 8.0 3.6 600 1 : 100,000 s Prilocaine 4% + epinephrine 60-90 180-480 g CALCULATION OF MILLIGRAMS OF 1 : 200,000 LOCAL ANESTHETIC PER DENTAL Bupivacaine 0.5% + >90 240-720 o CARTRIDGE (1.8 mL CARTRIDGE) epinephrine 1 : 200,000 Local Percent × 1.8 mL = l Anesthetic Concentration mg/mL mg/Cartridge b Articaine 4 40 72* Bupivacaine 0.5 5 9 . Lidocaine 2 20 36 y Mepivacaine 2 20 36 3 30 r54 Prilocaine 4 40 72 a MRD, Maximum recommended dose. *Cartridges of some drugs in the United States reard, “1.7 mL. each.” The actual volume of all local anesthetic cartridges is approximately 1.76 mL. b i l l a t n e d m o c . t o p s g o l b . y r a r b i l l a t n e d This page intentionally left blank m o c . t o p s g o l b . y r a r b i l l a t n e d m o c . t o p s g o l b . y r a r b Stanley F. Malamed, DDS i Professor of Anesthesia and Medicine l l School of Dentistry a University of Southern California t Los Angeles, California n with 441 illustrations e d m o c . t o p s g o l b . y r a r b i l l a t n e d m o To Beverly, Heather, Jennifer, and Jeremy, c and the next generation: Matthew, Rachel, Gabriella, Ashley, Rebecca, Elijah, and Ethan . t o p s g o l b . y r a r b i l l a t n e d This page intentionally left blank m o c . t o p s g o l b . y r a r b i l l a t n e d Contributors m Daniel L. Orr II, BS, DDS, MS (Anesthesiology), Mark N. Hochman, DDS o PhD, JD, MD Private Practice Limited to Periodontics Professor and Director Orthodontics and Implant Dentistry c Oral and Maxillofacial Surgery and Advanced Pain Control Specialized Dentistry of New York University of Nevada Las Vegas School of Dental Medicine New York City, New York . Las Vegas, Nevada Clinical Associate Professor t Clinical Professor New York University o Oral and Maxillofacial Surgery College of Dentistry University of Nevada School of Medicine New York City, New Yoprk Las Vegas, Nevada Clinical Consultant Milestone Scientisfic, Inc. Livingston, New Jersey g o l b . y r a r b i l l a t n e d vii This page intentionally left blank m o c . t o p s g o l b . y r a r b i l l a t n e d
Description: